Source: International Congress 2018 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Gurbanova (Tartu, Estonia), R. Mehdiyev (Baku, Azerbaijan), K. Blöndal (Reykjavik, Iceland), A. Altraja (Tartu, Estonia). Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons. 3680

Member's Comments

No comment yet.

Related content which might interest you: Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 New and repurposed drugs for MDR-TB patients Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence  Year: 2017 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007 Antituberculous drug resistance rates in soldier patients newly diagnosed with TB in Turkey Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB Source: ERJ Open Res, 5 (2) 00046-2019; 10.1183/23120541.00046-2019 Year: 2019 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Investigating trends in antituberculosis (anti-TB) drug resistance among treated patients of a university respiratory infections unit in Greece Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009